Minerva Neurosciences logo

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences Reports First Quarter 2016 Financial Results and Business Updates View HTML
Toggle Summary Minerva Neurosciences to Report First Quarter 2016 Financial Results and Business Updates on May 3, 2016
Management to host conference call
View HTML
Toggle Summary Minerva Neurosciences Reports Fiscal 2015 Fourth Quarter and Year End Financial Results and Business Updates View HTML
Toggle Summary Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202 View HTML
Toggle Summary Minerva Neurosciences to Report Fiscal 2015 Fourth Quarter and Year End Financial Results and Business Updates on March 14, 2016
Management to Host Conference Call
View HTML
Toggle Summary Minerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder View HTML
Toggle Summary Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients View HTML
Toggle Summary Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder
Consistent Improvements Observed With Selective Orexin-2 Receptor Antagonist in Multiple Parameters of Sleep Induction and Maintenance
View HTML
Toggle Summary Minerva Neurosciences Announces Update on MIN-101 Clinical Development Program
Enrollment Completed in European Phase IIb Trial and Investigational New Drug (IND) Application Accepted by U.S. FDA
View HTML
Toggle Summary Minerva Achieves Enrollment Target in Phase IIb Trial With MIN-101
WALTHAM, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has met its enrollment target of 234 patients in
View HTML
Displaying 151 - 160 of 194 results